about
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological ef...
Read More81 XNAS Volume
XNAS 16 May, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for Vaccinex Inc is on 23 May 2025 for the purpose of Vaccinex Inc Annual General Meeting for 2024
See details
Not Eligible
Expensive Valuation
Technically Bearish
Vaccinex Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..